Patents Examined by Kamal Saeed
  • Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
    Patent number: 11939324
    Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: March 26, 2024
    Assignees: reMYND N.V., Katholieke Universiteit Leuven
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom Francois L. Van Dooren, Arnaud Didier Marie Marchand, Amuri Kilonda, Sara Allasia, Patrick Chaltin
  • Amide compounds and method for making and using
    Patent number: 11939317
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: March 26, 2024
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Sphingosine pathway modulating compounds for the treatment of coronavirus infection
    Patent number: 11931344
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: March 19, 2024
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Elazar Rabbani
  • Uses of 4?-desferrithiocin analogs
    Patent number: 11931346
    Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a poly ether moiety at the 4?-position of the phenyl ring of the compound.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: March 19, 2024
    Assignee: University of Florida Research Foundation, Incorporated
    Inventor: Raymond J. Bergeron, Jr.
  • Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases
    Patent number: 11932652
    Abstract: The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and formula (II), tautomer thereof or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: March 19, 2024
    Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Yang Zhang, Wentao Wu, Zhixiang Li, Jian Qin, Jie Li, Zhen Gong, Jian Li, Shuhui Chen
  • Process for preparing aficamten
    Patent number: 11932631
    Abstract: Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: March 19, 2024
    Assignee: CYTOKINETICS, INC.
    Inventors: Denise Andersen, Matthew Pfeiffer, Norma Tom, Bradley P. Morgan
  • Solid dosage form having excellent stability
    Patent number: 11925648
    Abstract: The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: March 12, 2024
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Naoya Mizutani, Masayuki Morimoto, Maki Okabe, Masaaki Ito, Go Kimura
  • Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding
    Patent number: 11919855
    Abstract: Disclosed are substituted pyrrolidones and piperidones which may be utilized as EZH2 targeting agents. The substituted pyrrolidones and piperidones may include substituted 2-pyrrolidones and 2-piperidones. The disclosed pyrrolidones and piperidones may be used in pharmaceutical compositions and methods for treating cell proliferative disorders such as cancer.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 5, 2024
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Jindan Yu
  • Neprilysin inhibitors
    Patent number: 11919888
    Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: February 23, 2023
    Date of Patent: March 5, 2024
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia
    Patent number: 11918558
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: March 5, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • Compounds
    Patent number: 11911372
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 27, 2024
    Assignee: CTXT PTY LTD
    Inventors: Paul Anthony Stupple, Helen Rachel Lagiakos, Richard Charles Foitzik, Michelle Ang Camerino, George Nikolakopoulos, Ylva Elisabet Bergman Bozikis, Wilhelmus Johannes Antonius Kersten, Scott Raymond Walker, Jonathan Grant Hubert
  • Alkylaminoproline derivatives as alpha-2-delta-1 blockers
    Patent number: 11905243
    Abstract: The present invention relates to compounds showing pharmacological activity towards the subunit ?2?#of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels. More particularly, the invention relates to alkylaminoproline derivatives having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain and/or as neuroprotective agents.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: February 20, 2024
    Assignee: ACONDICIONAMIENTO TARRASENSE
    Inventors: Anita Wegert, Carmen Almansa-Rosales
  • Remdesivir treatment methods
    Patent number: 11903953
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11905275
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: February 20, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
    Patent number: 11905258
    Abstract: The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-?B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: February 20, 2024
    Assignee: Southern Research Institute
    Inventors: Mark J. Suto, Bini Mathew, Rita Cowell, Corinne E. Augelli-Szafran
  • Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders
    Patent number: 11897875
    Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: February 13, 2024
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
  • Oxazolidinone for treatment of infections with
    Patent number: 11896584
    Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: February 13, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, UNIVERSITY OF ST. THOMAS
    Inventors: Gyanu Lamichhane, J. Thomas Ippoliti
  • Compositions for treating acne and dermatological conditions
    Patent number: 11890260
    Abstract: The present disclosure generally relates to compositions comprising unique combinations of cannabinoids, antioxidants, and cofactors. The present disclosure also provides methods of making the compositions and methods for using the compositions for the treatment of mitochondrial ATP deficit disorders.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: February 6, 2024
    Assignee: Ilera Derm LLC
    Inventors: Brian Warrington, Karyn Grossman, Oludare Odumosu, Zoltan Kerekes
  • Substituted 2-aminobenzimidazoles analogs as antibiofilm agents
    Patent number: 11883384
    Abstract: In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: January 30, 2024
    Assignees: Ohio State Innovation Foundation, North Carolina State University
    Inventors: John Gunn, Laura Kuo, Christian Melander, William M. Huggins
  • 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole as an antitumor and antimicrobial compound
    Patent number: 11884637
    Abstract: A compound 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.
    Type: Grant
    Filed: August 28, 2023
    Date of Patent: January 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer, Sahar M. Mohamed, Mohammad Mahboob Alam